Brett Faine
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Brett Faine has a total of 271 co-authors. Here are the top co-authors by number of shared publications:
- Nicholas Matthew Mohr
Department of Emergency Medicine University of Iowa Carver College of Medicine Iowa City Iowa USA
22 shared publications - Azeemuddin Ahmed
Department of Emergency Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa
9 shared publications - Karisa K. Harland
Department of Emergency Medicine University of Iowa Health Care Iowa City Iowa USA
7 shared publications - Megan A. Rech
Department of Veterans Affairs, Center of Innovation for Complex Chronic Healthcare Edward Hines, Jr. VA Hospital Hines Illinois USA
6 shared publications Anne Zepeski
5 shared publications- Anne Zepeski
Department of Emergency Medicine (A.Z., N.M.M.), University of Iowa Carver College of Medicine, Iowa City
5 shared publications
Latest Publications
- Open Access
- 31 October 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (11)
Pilot Randomized Trial of Patient-Directed vs Fixed-Antibiotic Duration in Acute Pyelonephritis
In this multicenter double-blind pilot randomized trial, patient-directed antibiotic duration after symptom resolution demonstrated similar sustained clinical resolution and adverse events compared to fixed-duration treatment among women with pyelonephritis. These findings support the feasibility of this strategy and justify a larger, adequately powered randomized trial to evaluate efficacy and safety. Pyelonephritis; patient-directed antibiotic duration
- 31 October 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (11)
Open AccessPilot Randomized Trial of Patient-Directed vs Fixed-Antibiotic Duration in Acute Pyelonephritis
In this multicenter double-blind pilot randomized trial, patient-directed antibiotic duration after symptom resolution demonstrated similar sustained clinical resolution and adverse events compared to fixed-duration treatment among women with pyelonephritis. These findings support the feasibility of this strategy and justify a larger, adequately powered randomized trial to evaluate efficacy and safety. Pyelonephritis; patient-directed antibiotic duration
- 10 September 2026
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 9 (10) , e70291
A Cross‐Sectional Survey of Knowledge, Confidence, and Decision‐Making in Acute Stroke in the Era of Anti‐Amyloid Therapies
Background: Anti‐amyloid therapies (AATs) for Alzheimer's disease complicate emergency stroke care due to the risk of amyloid‐related imaging abnormalities (ARIA), which can mimic acute ischemic stroke (AIS) and increase hemorrhagic risk. We evaluated emergency medicine (EM) providers' (physicians and advanced practice providers) and pharmacists' knowledge, confidence, and clinical decision‐making related to AAT‐associated ARIA. Methods: A cross‐sectional, web‐based survey of EM providers and pharmacists practicing in United States hospital‐based emergency care settings between February and April 2026 was conducted. Survey domains included familiarity with AATs, confidence in ARIA recognition and management, clinical decision‐making, institutional preparedness, and barriers and facilitators to care. Results are reported descriptively, with subgroup comparisons between EM providers and pharmacists. Results: Clinical experience with AAT‐related scenarios was limited among the 204 survey participants; 77.5% reported no prior modification of thrombolytic or anticoagulant therapy because of AATs. Self‐reported knowledge of AATs was low (mean 2.4 ± 1.3 on a five‐point scale), and confidence in recognizing and managing ARIA was limited. EM pharmacists reported greater knowledge and higher confidence in medication‐related decision‐making than EM providers. Frequent barriers were unfamiliarity with AAT and ARIA, diagnostic overlap with acute ischemic stroke, and limited institutional resources. Most (83.3%) reported a need for additional education. Conclusions: EM providers and pharmacists demonstrated substantial gaps in preparedness for patients receiving AATs, including limited knowledge, low confidence, minimal clinical experience, and inadequate institutional support. These findings highlight opportunities for pharmacist‐led education, clinical decision support, and multidisciplinary implementation strategies to improve safe management of AAT‐associated neurologic emergencies as therapies continue to expand.
- 10 September 2026
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 9 (10) , e70291
A Cross‐Sectional Survey of Knowledge, Confidence, and Decision‐Making in Acute Stroke in the Era of Anti‐Amyloid Therapies
Background: Anti‐amyloid therapies (AATs) for Alzheimer's disease complicate emergency stroke care due to the risk of amyloid‐related imaging abnormalities (ARIA), which can mimic acute ischemic stroke (AIS) and increase hemorrhagic risk. We evaluated emergency medicine (EM) providers' (physicians and advanced practice providers) and pharmacists' knowledge, confidence, and clinical decision‐making related to AAT‐associated ARIA. Methods: A cross‐sectional, web‐based survey of EM providers and pharmacists practicing in United States hospital‐based emergency care settings between February and April 2026 was conducted. Survey domains included familiarity with AATs, confidence in ARIA recognition and management, clinical decision‐making, institutional preparedness, and barriers and facilitators to care. Results are reported descriptively, with subgroup comparisons between EM providers and pharmacists. Results: Clinical experience with AAT‐related scenarios was limited among the 204 survey participants; 77.5% reported no prior modification of thrombolytic or anticoagulant therapy because of AATs. Self‐reported knowledge of AATs was low (mean 2.4 ± 1.3 on a five‐point scale), and confidence in recognizing and managing ARIA was limited. EM pharmacists reported greater knowledge and higher confidence in medication‐related decision‐making than EM providers. Frequent barriers were unfamiliarity with AAT and ARIA, diagnostic overlap with acute ischemic stroke, and limited institutional resources. Most (83.3%) reported a need for additional education. Conclusions: EM providers and pharmacists demonstrated substantial gaps in preparedness for patients receiving AATs, including limited knowledge, low confidence, minimal clinical experience, and inadequate institutional support. These findings highlight opportunities for pharmacist‐led education, clinical decision support, and multidisciplinary implementation strategies to improve safe management of AAT‐associated neurologic emergencies as therapies continue to expand.
- Open Access
- 1 September 2026
- Published by Wolters Kluwer Health in Neurology Open Access
- Vol. 2 (3) , e000100
Association of Thromboelastography With Hematoma Expansion and Disability in Spontaneous Intracerebral Hemorrhage
Background and ObjectivesHematoma expansion (HE), an increase in bleeding into the brain, is a modifiable cause of disability and death after intracerebral hemorrhage (ICH). Some specialized hemost...
- 1 September 2026
- Published by Wolters Kluwer Health in Neurology Open Access
- Vol. 2 (3) , e000100
Open AccessAssociation of Thromboelastography With Hematoma Expansion and Disability in Spontaneous Intracerebral Hemorrhage
Background and ObjectivesHematoma expansion (HE), an increase in bleeding into the brain, is a modifiable cause of disability and death after intracerebral hemorrhage (ICH). Some specialized hemost...
- Open Access
- 6 July 2026
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 9 (7) , e70246
Consensus Recommendations for Clinical Pharmacist Integration into the Acute Stroke Care Team: Endorsed by the American College of Clinical Pharmacy, Neurocritical Care Society, Society for Academic Emergency Medicine, and Society of Critical Care Medicine, and affirmed by the American Academy of Neurology
Clinical pharmacists are increasingly recognized as vital contributors to acute stroke care, yet their role remains inconsistently defined and underutilized across health care systems. This consensus statement explores the expanding presence of clinical pharmacists within interdisciplinary stroke teams, particularly in the management of both acute ischemic stroke ( AIS ) and hemorrhagic stroke. This consensus statement panel was composed of clinical pharmacists, emergency medicine physicians, and a vascular neurologist. The Grading of Recommendations, Assessment, Development, and Evaluation ( GRADE ) approach was used to assess the level of certainty and strength of recommendations. We focused on two questions regarding the clinical pharmacist's role in caring for adult patients presenting to the emergency department ( ED ) with AIS or hemorrhagic stroke. Despite the very low level of evidence, a consensus was reached for the following recommendations: (1) clinical pharmacist involvement in AIS care for adult patients presenting to the ED and (2) clinical pharmacist involvement in hemorrhagic stroke care for adult patients presenting to the ED . Based on the available literature, we believe optimizing the clinical pharmacist role is a critical factor in improving time‐sensitive treatment and equity in care delivery.
- 6 July 2026
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 9 (7) , e70246
Open AccessConsensus Recommendations for Clinical Pharmacist Integration into the Acute Stroke Care Team: Endorsed by the American College of Clinical Pharmacy, Neurocritical Care Society, Society for Academic Emergency Medicine, and Society of Critical Care Medicine, and affirmed by the American Academy of Neurology
Clinical pharmacists are increasingly recognized as vital contributors to acute stroke care, yet their role remains inconsistently defined and underutilized across health care systems. This consensus statement explores the expanding presence of clinical pharmacists within interdisciplinary stroke teams, particularly in the management of both acute ischemic stroke ( AIS ) and hemorrhagic stroke. This consensus statement panel was composed of clinical pharmacists, emergency medicine physicians, and a vascular neurologist. The Grading of Recommendations, Assessment, Development, and Evaluation ( GRADE ) approach was used to assess the level of certainty and strength of recommendations. We focused on two questions regarding the clinical pharmacist's role in caring for adult patients presenting to the emergency department ( ED ) with AIS or hemorrhagic stroke. Despite the very low level of evidence, a consensus was reached for the following recommendations: (1) clinical pharmacist involvement in AIS care for adult patients presenting to the ED and (2) clinical pharmacist involvement in hemorrhagic stroke care for adult patients presenting to the ED . Based on the available literature, we believe optimizing the clinical pharmacist role is a critical factor in improving time‐sensitive treatment and equity in care delivery.
- Open Access
- 16 June 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (12) , e049124
Minimal Fibrinolysis After Acute Intracerebral Hemorrhage Undercuts the Mechanism of Tranexamic Acid
- 16 June 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (12) , e049124
Open AccessMinimal Fibrinolysis After Acute Intracerebral Hemorrhage Undercuts the Mechanism of Tranexamic Acid
- Open Access
- 8 May 2026
- Published by Wiley in Academic Emergency Medicine
- Vol. 33 (5) , e70316
Emergency Medicine Funding Within NIH Is the Least Concentrated of Any Specialty
- 8 May 2026
- Published by Wiley in Academic Emergency Medicine
- Vol. 33 (5) , e70316
Open AccessEmergency Medicine Funding Within NIH Is the Least Concentrated of Any Specialty
- 27 November 2025
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 9 (2) , e70156
Evaluation of Emergency Medicine Pharmacist Participation in Time to Oral Anticoagulation Reversal: A Systematic Review and Meta‐Analysis
Background: Intracranial and extracranial hemorrhages are significant causes of morbidity and mortality. Emergency medicine pharmacists (EMPs) can play a crucial role in anticoagulation reversal by identifying patients on anticoagulation, selecting the optimal anticoagulation reversal agent, and ensuring adequate dosing and prompt administration. The goal of this systematic review and meta‐analysis was to determine the impact EMPs have on time to anticoagulation reversal and patient outcomes in anticoagulation‐associated hemorrhages. Methods: A medical librarian performed a literature search in EBSCO CINAHL, Ovid Cochrane Central Register of Controlled Trials, Ovid Embase, Ovid Medline, Scopus, and Web of Science Core Collection from inception to January 2025 for all types of oral anticoagulants and for life‐threatening bleeding that required emergent reversal. Newcastle‐Ottawa was used to assess the risk of bias, and Grading of Recommendations Assessment, Development, and Evaluation (GRADE) was used to assess the level of certainty of the evidence. Random effects models estimating mean differences and 95% confidence intervals are reported. Results: There were 2445 titles and abstracts screened, with 44 undergoing full‐text evaluation. Six observational studies including 219 patients who received an anticoagulation reversal agent with the presence of an EMP and 198 patients who received a reversal agent without an EMP were included. Time from emergency department (ED) presentation to anticoagulation reversal agent administration (75.60 min, 95% confidence interval [CI]: −101.7 to −49.5) and time from medication order to administration were faster with an EMP (−18.7 min, 95% CI: −23.5 to −14.0). There was no difference in short‐term mortality. The included studies had a high risk of bias and were deemed very low quality of evidence. Conclusion: EMP involvement in patient care during anticoagulation reversal of acute hemorrhages improved time to anticoagulation reversal agent administration. Larger scale, higher‐quality studies are necessary to assess the value of EMPs in improving patient‐centered outcomes.
- 27 November 2025
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 9 (2) , e70156
Evaluation of Emergency Medicine Pharmacist Participation in Time to Oral Anticoagulation Reversal: A Systematic Review and Meta‐Analysis
Background: Intracranial and extracranial hemorrhages are significant causes of morbidity and mortality. Emergency medicine pharmacists (EMPs) can play a crucial role in anticoagulation reversal by identifying patients on anticoagulation, selecting the optimal anticoagulation reversal agent, and ensuring adequate dosing and prompt administration. The goal of this systematic review and meta‐analysis was to determine the impact EMPs have on time to anticoagulation reversal and patient outcomes in anticoagulation‐associated hemorrhages. Methods: A medical librarian performed a literature search in EBSCO CINAHL, Ovid Cochrane Central Register of Controlled Trials, Ovid Embase, Ovid Medline, Scopus, and Web of Science Core Collection from inception to January 2025 for all types of oral anticoagulants and for life‐threatening bleeding that required emergent reversal. Newcastle‐Ottawa was used to assess the risk of bias, and Grading of Recommendations Assessment, Development, and Evaluation (GRADE) was used to assess the level of certainty of the evidence. Random effects models estimating mean differences and 95% confidence intervals are reported. Results: There were 2445 titles and abstracts screened, with 44 undergoing full‐text evaluation. Six observational studies including 219 patients who received an anticoagulation reversal agent with the presence of an EMP and 198 patients who received a reversal agent without an EMP were included. Time from emergency department (ED) presentation to anticoagulation reversal agent administration (75.60 min, 95% confidence interval [CI]: −101.7 to −49.5) and time from medication order to administration were faster with an EMP (−18.7 min, 95% CI: −23.5 to −14.0). There was no difference in short‐term mortality. The included studies had a high risk of bias and were deemed very low quality of evidence. Conclusion: EMP involvement in patient care during anticoagulation reversal of acute hemorrhages improved time to anticoagulation reversal agent administration. Larger scale, higher‐quality studies are necessary to assess the value of EMPs in improving patient‐centered outcomes.
- 9 August 2025
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 98, 57-64
Assessing the impact of emergency medicine pharmacists on fibrinolytic door-to-needle times in acute ischemic stroke: A systematic review and meta-analysis (Pharmacist-assisted Stroke Treatments I (PhAST-1))
- 9 August 2025
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 98, 57-64
Assessing the impact of emergency medicine pharmacists on fibrinolytic door-to-needle times in acute ischemic stroke: A systematic review and meta-analysis (Pharmacist-assisted Stroke Treatments I (PhAST-1))